Posted on 31 January 2014.
Aosaikang Pharmaceutical Postpones 9 Million Shenzhen IPO (1)
The Nanjing-based maker of cancer drugs delayed the offering on Shenzhen's ChiNext board until an unspecified date because the sale would have been “relatively large,” it said in a statement to the exchange dated today. The sale valued Aosaikang at 67 …
Read more on Businessweek